Product Description
Xanamem is an inhibitor of 11_-hydroxysteroid dehydrogenase type 1, an enzyme in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response.
Mechanisms of Action: 11beta-HSD1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral, Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Actinogen Medical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United Kingdom, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease|Cognitive Dysfunction|Depressive Disorder, Major|Follicular Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06125951 |
XanaMIA | P2 |
Active, not recruiting |
Alzheimer Disease|Follicular Lymphoma |
2026-10-01 |
12% |
2025-12-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05657691 |
XanaCIDD | P2 |
Completed |
Depressive Disorder, Major|Cognitive Dysfunction |
2024-07-01 |
50% |
2024-07-11 |
Primary Endpoints |
ACTRN12625000662460 |
ACTRN12625000662460 | P1 |
Recruiting |
Alzheimer Disease|Depressive Disorder, Major |
2025-06-24 |
2025-07-26 |
Treatments |